{
    "clinical_study": {
        "@rank": "51807", 
        "acronym": "LAKIS", 
        "arm_group": [
            {
                "arm_group_label": "Conventional therapy", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Standard of care as protocolized locally"
            }, 
            {
                "arm_group_label": "Levosimendan", 
                "arm_group_type": "Experimental", 
                "description": "The experimental group receives standard treatment supplemented by levosimendan  (0.2 \u00b5g/kg/min) for 24 hours within 36 hrs following onset of AKI."
            }
        ], 
        "brief_summary": {
            "textblock": "We hypothesise that levosimendan will have a positive influence on renal function during\n      acute kidney injury in adult intensive care patients."
        }, 
        "brief_title": "Levosimendan in Acute Kidney Injury Study", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Kidney Injury", 
        "condition_browse": {
            "mesh_term": [
                "Acute Kidney Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this trial is to evaluate whether the use of levosimendan is able to improve\n      renal function."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinically diagnosed adult patients with AKI\n\n        Exclusion Criteria:\n\n          -  Failure to obtain written consent to participate from patient or legal representative\n             (by deferred consent)\n\n          -  Patients entering the ICU for post-operative observation with an estimated length of\n             stay less than 24 hrs.\n\n          -  Moribund patients\n\n          -  Patients under the age of 18\n\n          -  Pregnancy\n\n          -  Patients suffering from pre-existing renal failure (elevated NGAL values without\n             apparent rise in creatinine values)\n\n          -  Renal replacement therapy initiated before admission due to Chronic Kidney Disease\n\n          -  Hypersensitivity to levosimendan experienced by previous treatments\n\n          -  Severe hypotension and tachycardia\n\n          -  Significant mechanical obstruction affecting ventricular filling or outflow or both.\n\n          -  Severe hepatic impairment (ALAT/ASAT>400U/L)\n\n          -  Patients will be excluded if the treating physician judges that study participation\n             is undesirable for medical, medical-ethical or other reasons\n\n          -  Known history of Torsades de Pointes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720030", 
            "org_study_id": "Levosimendan in AKI Study"
        }, 
        "intervention": [
            {
                "arm_group_label": "Levosimendan", 
                "description": "Verum therapy", 
                "intervention_name": "Levosimendan", 
                "intervention_type": "Drug", 
                "other_name": "Simdax (R)"
            }, 
            {
                "arm_group_label": "Conventional therapy", 
                "description": "Placebo therapy to safeguard blinding", 
                "intervention_name": "Conventional therapy", 
                "intervention_type": "Drug", 
                "other_name": "Standard care plus placebo comparator"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Simendan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Renal", 
            "Acute Kidney Injury", 
            "AKI", 
            "Levosimendan", 
            "Simdax", 
            "Renal perfusion", 
            "Mortality", 
            "Renal flow"
        ], 
        "lastchanged_date": "October 7, 2013", 
        "location": {
            "contact": {
                "email": "jlenoble@viecuri.nl", 
                "last_name": "Jos le Noble, MD, Ph.D", 
                "phone": "+31 (0)77-3205785"
            }, 
            "facility": {
                "address": {
                    "city": "Venlo", 
                    "country": "Netherlands", 
                    "state": "Limburg", 
                    "zip": "NL-5912 BL"
                }, 
                "name": "VieCuri Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective, Randomized, Monocenter, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Levosimendan in Intensive Care Patients With Acute Kidney Injury", 
        "overall_official": {
            "affiliation": "VieCuri Medical Centre", 
            "last_name": "Jos Le Noble, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Netherlands: Medical Ethics Review Committee (METC)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Daily analysis of kidney function expressed in endogenous creatinine clearance", 
                "measure": "Change in renal function", 
                "safety_issue": "No", 
                "time_frame": "Baseline and every 24 hours until end ICU stay"
            }, 
            {
                "description": "Survival of included AKI patients in our ICU measured at day 28", 
                "measure": "Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720030"
        }, 
        "responsible_party": {
            "investigator_affiliation": "VieCuri Medical Centre", 
            "investigator_full_name": "Dr. Jos le Noble", 
            "investigator_title": "PhD, MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "VieCuri Medical Centre", 
        "sponsors": {
            "collaborator": {
                "agency": "Orion Corporation, Orion Pharma", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "VieCuri Medical Centre", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}